Page last updated: 2024-08-24

valsartan and vericiguat

valsartan has been researched along with vericiguat in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's7 (100.00)2.80

Authors

AuthorsStudies
Aimo, A; Bayes-Genis, A; Emdin, M; Georgiopoulos, G; Lombardi, CM; Passino, C; Pateras, K; Stamatelopoulos, K1
Felker, GM; Mann, DL1
Gronda, E; Iacoviello, M; Palazzuoli, A1
Gallo, G; Rubattu, S; Volpe, M1
Grimm, D; Norre, T; Simonsen, U1
Alemayehu, WG; Armstrong, PW; Butler, J; Edelmann, F; Ezekowitz, J; Hernandez, AF; Lam, CSP; McMullan, C; O'Connor, CM; Pieske, B; Ponikowski, P; Roessig, L; Senni, M; Sim, D; Voors, AA; Westerhout, CM1
Butt, JH; McMurray, JJV1

Reviews

4 review(s) available for valsartan and vericiguat

ArticleYear
Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis.
    Cardiovascular drugs and therapy, 2021, Volume: 35, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials, Phase III as Topic; Drug Combinations; Heart Failure; Heterocyclic Compounds, 2-Ring; Hospitalization; Humans; Network Meta-Analysis; Pyrimidines; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Valsartan

2021
Mechanisms and Models in Heart Failure: A Translational Approach.
    Circulation research, 2021, 05-14, Volume: 128, Issue:10

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials, Phase III as Topic; Drug Combinations; Drug Development; Enzyme Activators; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Models, Biological; Natriuretic Peptides; Neprilysin; Pyrimidines; Sodium-Glucose Transporter 2 Inhibitors; Soluble Guanylyl Cyclase; Stroke Volume; Urea; Valsartan; Ventricular Remodeling

2021
Recent advances in pharmacological treatment of heart failure.
    European journal of clinical investigation, 2021, Volume: 51, Issue:11

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiotonic Agents; Drug Combinations; Ferric Compounds; Heart Failure; Heterocyclic Compounds, 2-Ring; Hospitalization; Humans; Iron Deficiencies; Maltose; Pyrimidines; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Urea; Valsartan; Vasodilator Agents; Ventricular Remodeling

2021
Sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy.
    Basic & clinical pharmacology & toxicology, 2022, Volume: 130, Issue:4

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Glucose; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Pyrimidines; Sodium; Tetrazoles; Treatment Outcome; Valsartan

2022

Trials

1 trial(s) available for valsartan and vericiguat

ArticleYear
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial.
    European journal of heart failure, 2022, Volume: 24, Issue:9

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Hyperkalemia; Hypotension; Pyrimidines; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left

2022

Other Studies

2 other study(ies) available for valsartan and vericiguat

ArticleYear
Targeting Cyclic Guanylate Monophosphate in Resistant Hypertension and Heart Failure: Are Sacubitril/Valsartan and Vericiguat Synergistic and Effective in Both Conditions?
    High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2021, Volume: 28, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Hypertension; Neprilysin; Pyrimidines; Stroke Volume; Tetrazoles; Valsartan

2021
Vericiguat, sacubitril/valsartan and more evidence that we are failing our patients.
    European journal of heart failure, 2022, Volume: 24, Issue:9

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Pyrimidines; Stroke Volume; Tetrazoles; Valsartan

2022